United Therapeutics has agreed to pay $800 million upfront to Arena Pharmaceuticals in exchange for worldwide rights to the latter's ralinepag for pulmonary arterial hypertension, which is being tested in a late-stage trial. Aside from royalties from sales, Arena could receive $150 million if the drug gains approval from a key non-US market and $250 million if the inhaled version of the medication gains FDA approval.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.